Drugs / SL-28
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07341737 | Jul 2026 → Jan 2027 expected | breast cancer, colorectal cancer, cutaneous melanoma, endometrial cancer +10 | Second Life Therapeutics | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06872489 | — | cancer of unknown primary site, head and neck cancer, malignant pancreatic neoplasm, neuroblastoma +1 | Second Life Therapeutics | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Second Life Therapeutics | Results Second Life Therapeutics Presents SL-28 Complete Response Case Report at the American Thoracic Society 2026 International Conference secondlifetherapeutics.com ↗
Novel off-the-shelf cell therapy SL-28 was associated with complete response in a patient with malignant pleural effusion under compassionate use. |
| 2025-10-30 | Second Life Therapeutics | Results Regulating white blood cell activity through the novel universal receptive system secondlifetherapeutics.com ↗
Second Life Therapeutics announced the publication of a case report abstract in the American Journal of Respiratory and Critical Care Medicine supplement describing a complete response in a patient with stage IV non-small cell lung cancer and malignant pleural effusion treated with SL-28, the company’s investigational allogeneic cell therapy. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Second Life Therapeutics | Second Life Therapeutics Presents SL-28 Complete Response Case Report at the American Thoracic Society 2026 International Conference secondlifetherapeutics.com ↗ |
| 2025-10-30 | Second Life Therapeutics | Regulating white blood cell activity through the novel universal receptive system secondlifetherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL-28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07341737 ↗ |
| Modality | Cell therapy | “SL-28 is a cell-based therapy” NCT06872489 ↗ |
| Route | Intravenous | “Patients receive SL-28 IV once daily on days 1-5 and 8-12.” NCT06872489 ↗ |